Abstract
About 40 – 60% of the patients with prostate cancer in the hormone independent stage respond to a secondary hormonal manipulation with a temporary decrease of the serum prostate-specific antigen (PSA). PSA progression can be delayed for 4 – 8 months and the onset of a taxane-based chemotherapy with its potentially toxic side effects can be postponed. Traditionally second line antiandrogens, inhibitors of adrenal testosterone production, estrogens or progestin have been applied in secondary hormonal manipulation. Recently somatostatin analogs have been suggested for the treatment of hormone independent prostate cancer. By modulating intracellular pro-proliferative and anti-apoptotic signaling cascades somatostatin analogs influence the tumor cell micro-environment and inhibit tumor progression. In this review we focus on the mode of action and the clinical application of somatostatin analogs in the treatment of hormone- independent prostate cancer. The concept of an “anti-survival factor therapy” is discussed.
Keywords: Prostate cancer, antisurvival factor, prognosis, hormone independence, somatostatin analogs, secondary hormonal treatment, serum, chemotherapy, estrogens, cyclic peptide hormone, half life, inhibit, adrenocorticotropic hormone, pituitary tumors, apoptosis, stromal cell, cell cycle, electrolyte dysbalance, hypoglycemia, gastrointestinal, Dose dependency, vincristine, incubation, hormone sensitivity, sensitization, efficacy, diarrhea, nausea, Biochemical, monotherapy, metastatic regression, survival factor, pain, lymph, neutropenia, glucagon, lethal, oestrogens, corticosteroids
Current Cancer Therapy Reviews
Title: “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Volume: 7 Issue: 1
Author(s): David Schilling, Rainer Kufer, Stephan Kruck, Sandra Waalkes, Arnulf Stenzl, Markus A. Kuczyk and Axel S. Merseburger
Affiliation:
Keywords: Prostate cancer, antisurvival factor, prognosis, hormone independence, somatostatin analogs, secondary hormonal treatment, serum, chemotherapy, estrogens, cyclic peptide hormone, half life, inhibit, adrenocorticotropic hormone, pituitary tumors, apoptosis, stromal cell, cell cycle, electrolyte dysbalance, hypoglycemia, gastrointestinal, Dose dependency, vincristine, incubation, hormone sensitivity, sensitization, efficacy, diarrhea, nausea, Biochemical, monotherapy, metastatic regression, survival factor, pain, lymph, neutropenia, glucagon, lethal, oestrogens, corticosteroids
Abstract: About 40 – 60% of the patients with prostate cancer in the hormone independent stage respond to a secondary hormonal manipulation with a temporary decrease of the serum prostate-specific antigen (PSA). PSA progression can be delayed for 4 – 8 months and the onset of a taxane-based chemotherapy with its potentially toxic side effects can be postponed. Traditionally second line antiandrogens, inhibitors of adrenal testosterone production, estrogens or progestin have been applied in secondary hormonal manipulation. Recently somatostatin analogs have been suggested for the treatment of hormone independent prostate cancer. By modulating intracellular pro-proliferative and anti-apoptotic signaling cascades somatostatin analogs influence the tumor cell micro-environment and inhibit tumor progression. In this review we focus on the mode of action and the clinical application of somatostatin analogs in the treatment of hormone- independent prostate cancer. The concept of an “anti-survival factor therapy” is discussed.
Export Options
About this article
Cite this article as:
Schilling David, Kufer Rainer, Kruck Stephan, Waalkes Sandra, Stenzl Arnulf, A. Kuczyk Markus and S. Merseburger Axel, “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs, Current Cancer Therapy Reviews 2011; 7 (1) . https://dx.doi.org/10.2174/157339411794474173
DOI https://dx.doi.org/10.2174/157339411794474173 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Current Drug Targets The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design In Silico Modeling of Crabtree Effect
Endocrine, Metabolic & Immune Disorders - Drug Targets Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Laparoscopic Reconstructive Surgery in Pediatric Urology: An Overview of Current Options
Current Pediatric Reviews The Crosstalk between Gut Microbiota, Intestinal Immunological Niche and Visceral Adipose Tissue as a New Model for the Pathogenesis of Metabolic and Inflammatory Diseases: The Paradigm of Type 2 Diabetes Mellitus
Current Medicinal Chemistry Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Anterior Gradient-2 Pathway as a Model for Developing Peptide-Aptamer Anti-Cancer Drug Leads that Stimulate p53 Function
Current Chemical Biology Flavonoids: Recent Advances as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism New Approaches in Data Integration for Systems Chemical Biology
Current Topics in Medicinal Chemistry Recent Patents on Interventional Robot for Prostate Cancer
Recent Patents on Mechanical Engineering Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Targeting Apoptosis to Treat Multiple Sclerosis
Current Drug Discovery Technologies Xanthohumol, a Prenylated Chalcone Derived from Hops, Suppresses Cancer Cell Invasion through Inhibiting the Expression of CXCR4 Chemokine Receptor
Current Molecular Medicine